Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Guided Posters


ea0056gp172 | Parathyroid | ECE2018

A pilot study of the differences in miRNA expression profile in the blood serum between patients with malignant and benign parathyroid tumors

Krupinova Julia , Petrov Natalia Mokrysheva Vasiliy , Pigarova Ekaterina , Dzeranova Larisa , Tiulpakov Anatoliy

Background: MiRNAs are small non-coding RNAs, which regulate biological and pathological processes, including organogenesis, apoptosis, cell proliferation and differentiation. Considering the complexity of the parathyroid cancer (PC) diagnosis, discovering of new markers of the disease, which may help to evaluate the prognosis before surgical treatment, becomes an important problem. We studied the differences in miRNA expression profile in the blood serum between patients with...

ea0056gp173 | Parathyroid | ECE2018

Excess of parathyroid hyperplasia incidence in subjects exposed to ionizing radiation after the CHNPP accident

Kaminskyi Oleksii , Kopilova Olga , Afanasyev Dmitryi , Loganovskyi Kontantin , Talko Viktoria , Mazurenko Olga , Grishcenko Katerina , Tsvet Larisa , Bazyka Dmitrii

Parathyroid glands are critical not only for regulation of the phosphorous-calcium metabolism, but also have a key role in the function of nervous, cardiovascular, digestive and other human body systems. Parathyroids are capable of accumulating the isotopes of cesium, strontium and radioactive iodine, which can lead to parathyroid cell damage and emergence of glandular dysfunction. Significant radioactive environmental releases and fallout after the Chernobyl NPP accident in 1...

ea0056gp174 | Parathyroid | ECE2018

The design and preliminary results of a phase 1 TransCon PTH trial in healthy volunteers

Karpf David , Mortensen Eva , Sprogoe Kennett , Pihl Susanne , Leff Jonathan

Background: Hypoparathyroidism (HP), a condition of parathyroid hormone (PTH) deficiency, leads to abnormal calcium metabolism. Standard of care (SOC), ie, large amounts of calcium and active vitamin D, leads to hypercalciuria and increased calcium x phosphate. Daily Natpara, PTH(1-84), injections reduced calcium and active vitamin D doses but not 24-hour urinary calcium (uCa) excretion or incidence of hypo- and hypercalcemia due to its 3-hour half-life (Natpara label). NIH st...

ea0056gp175 | Parathyroid | ECE2018

Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement

Mantovani Giovanna , Lecumberri Beatriz , Bastepe Murat , Monk David , de Sanctis Luisa , Thiele Susanne , Usardi Alessia , Ahmed Faisal , Bufo Roberto , Choplin Timothee , DeFilippo Gianpaolo , Devernois Guillemette , Eggermann Thomas , Elli Francesca , Freson Kathleen , Ramirez Aurora Garcia , Germain-Lee Emily , Groussin Lionel , Hamdy Neveen , Hanna Patrick , Hiort Olaf , Juppner Harald , Kamenicky Peter , Knight Nina , Kottler Marie-Laure , Le Norcy Elvire , Levine Michael A , Makitie Outi , Martin Regina , Martos-Moreno Gabriel Angel , Minagawa Masanori , Murray Philip , Pereda Arrate , Pignolo Robert , Rejnmark Lars , Rodado Rebecca , Rothenbuhler Anya , Saraff Vrinda , Shoemaker Ashley , Shore Eileen M , Silve Caroline , Turan Serap , Woods Philip , Zillikens M Carola , de Nanclares Guiomar Perez , Linglart Agnes

Pseudohypoparathyroidism (PHP) and related disorders lead to a wide spectrum of abnormal physical characteristics, neurocognitive and endocrine abnormalities that share a common PTH/PTHrP signaling pathway. The clinical and molecular overlap of PHP and related disorders lead to difficulties in clinical and molecular diagnosis which prompt to the possibility of incorrect management of these patients. PHP (including all subtypes), pseudoPHP, acrodysostosis and progressive osseou...

ea0056gp176 | Parathyroid | ECE2018

Symptom burden and HRQoL reported among patients with chronic hypoparathyroidism: impact of treatment with rhPTH (1-84) and with standard therapy

Chen Kristina , Hadker Nandini , Abibova Irana , Hanbury-Brown Lachlan , Vera-Llonch Montserrat , Clarke Bart

Chronic hypoparathyroidism (HypoPT) is a rare disease associated with a variety of symptoms and diminished health-related quality of life (HRQoL). This study aimed to characterise and quantify the symptom burden, HRQoL, and overall disease impact in patients receiving recombinant human parathyroid hormone (rhPTH1-84, Natpar®) for inadequately controlled HypoPT and in symptomatic patients receiving standard therapy (ST; calcium and/or vitamin D supplements). A w...

ea0056gp177 | Parathyroid | ECE2018

Maintenance of key biochemical parameters with recombinant human parathyroid hormone (1-84) in patients with hypoparathyroidism: an analysis of a long-term, open-label, single-centre study

Krasner Alan , Cusano Natalie E , Rubin Mishaela R , Piccolo Rebecca , Bilezikian John P

Hypoparathyroidism is a rare disorder characterised by hypocalcaemia and insufficient or undetectable parathyroid hormone (PTH). Recombinant human PTH, rhPTH(1-84), has been approved in the United States and Europe as an adjunctive treatment for adult patients with hypoparathyroidism. When hypoparathyroidism is established, long-term administration of rhPTH(1-84) is a treatment option. Thus, long-term safety and efficacy data for rhPTH(1-84) are needed. To this end, we evaluat...

ea0056gp178 | Parathyroid | ECE2018

The global, prospective, observational PARADIGHM registry for patients with chronic hypoparathyroidism was expanded to capture recombinant human parathyroid hormone, rhPTH(1-84), use under routine clinical care

Clarke Bart L , Rejnmark Lars , Brandi Maria Luisa , Germak John , Hahner Stefanie , Houillier Pascal , Kampe Olle , Kasperk Christian , Khan Aliya , Levine Michael A , Mannstadt Michael , Piccolo Rebecca , Shoback Dolores M , Vokes Tamara J , Gittoes Neil

PARADIGHM™, a global, prospective, observational registry of patients with chronic hypoparathyroidism (HPT), began enrolment in 2013 to collect data on the natural history of chronic HPT ( NCT01922440). Since initiation, recombinant human PTH, rhPTH(1-84), has been approved in the United States and Europe as an adjunctive treatment for adult patients with HPT. The protocol for the registry (now a European Medicines Agency–designated postm...

ea0056gp179 | Parathyroid | ECE2018

Stone risk profile analysis in patients with asymptomatic primary hyperparathyroidism

Saponaro Federica , Cetani Filomena , Di Giulio Marina , Mazoni Laura , Apicella Matteo , Pardi Elena , Borsari Simona , Marcocci Claudio

The kidney is an important target of primary hyperparathyroidism (PHPT). The 4th International Workshop for the management of Asymptomatic PHPT included the presence of hypercalciuria (24-h urinary calcium > 400 mg/day) and increased stone risk by biochemical stone risk profile as criteria for surgery. Increased stone risk profile was defined as at least one between ßCaOx>4 and ßHPO4>2, as defined in literature in a different study population. The aim of ...

ea0056gp180 | Parathyroid | ECE2018

Five-year efficacy and safety of recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) for the treatment of adults with chronic hypoparathyroidism: analysis from the open-label race study

Clarke Bart L , Shoback Dolores M , Bilezikian John P , Bone Henry , Denham Douglas , Levine Michael A , Mannstadt Michael , Peacock Munro , Rothman Jeffrey , Vokes Tamara J , Warren Mark L , Watts Nelson B , Lee Hak-Myung , Sherry Nicole

Hypoparathyroidism is a disorder of mineral homoeostasis due to parathyroid hormone (PTH) deficiency. Conventional treatment with oral Ca and calcitriol may maintain serum Ca levels but does not replace other physiologic PTH effects. RACE is an ongoing open-label study of recombinant human PTH1-84 (rhPTH1-84) for hypoparathyroidism treatment in adults ( NCT01297309). Patients initially received rhPTH1-84 25 or 50 μg/day subcutaneously, with 25-μg in...

ea0056gp181 | Parathyroid | ECE2018

Is there HIV-associated hypoparathyroidism?

Noe Sebastian , Heldwein Silke , Oldenbuttel Celia , Jager Hans , Wolf Eva

Background: Parathyroid hormone (PTH) secretion in response to hypocalcemia was found to be altered in people living with HIV (PLWH) and HIV infection has therefore been acknowledged as a potential reason for hypoparathyroidism (HPO).Aim: To describe the prevalence of HPO in a population of PLWH.Methods: Monocentric, retrospective sub-study of the Munich ArcHIV cohort.Results: 579 patients (461 men (79.6%)) w...

ea0056gp182 | Parathyroid | ECE2018

Use of a Disease-Characteristic Questionnaire identified pain and cramps and neuro-vegetative symptoms as significantly elevated and affected by Medication in mainly well-controlled hypoparathyroid patients

Wilde Deborah , Wilken Lara , Stamm Bettina , Heppner Christina , Leha Andreas , Herrmann-Lingen Christoph , Siggelkow Heide

Introduction: Hypoparathyroidism (hypoPT) is characterized by inadequately low circulating concentrations of parathyroid hormone (PTH) followed by low calcium and increased phosphate levels in the blood. Patients with hypoPT suffer from a number of complications and complaints including infections, neuro-psychiatric diseases, abnormal bone architecture impaired muscle function and reduced quality of life. Due to the complexity of the various clinical manifestations there is a ...

ea0056gp183 | Parathyroid | ECE2018

A novel mutation in the calcium sensing receptor GENE IN AN Italian family affected by autosomal dominant hypocalcemia

Mazoni Laura , Borsari Simona , Pardi Elena , Saponaro Federica , Banti Chiara , Marconcini Giulia , Marcocci Claudio , Cetani Filomena

The G protein-coupled calcium sensing receptor (CaSR), widely expressed on the surface of parathyroid chief cells and in the kidney, plays a central role in calcium homeostasis. Activating mutations of CaSR gene are responsible for autosomal dominant hypocalcemia (ADH), a rare disorder caused by hypocalcemia, hyperphosphatemia, hypercalciuria and inadequately low concentration of parathyroid hormone (PTH). In this study, we report a family affected by ADH. The proband...